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ABSTRACT 
The complexity and continuous evolution of cancer make the design of novel 
strategies of treatment a constant challenge in biomedicine.  Moreover, most of cancer 
treatments are still not tumor-specific and provoke high systemic toxicity. Herein we 
have developed a novel selective nanodevice to eliminate tumor cells while leaving 
healthy ones intact. To achieve this objective, a polyplex carrier, comprising an elastin 
like-recombinamer covalently conjugated to an aptamer and complexed with therapeutic 
DNA, was tested. This carrier forms a double-lock multifunctional device due to 
specific binding to a tumor cell marker and the selective expression of therapeutic DNA 
inside human breast-cancer cells. Due to the stability provided by ELRs, the 
homogeneous population of polyplexes obtained showed selective toxicity against 
cancer cells in in vitro and  in vivo assay. Inhibition of tumor progression was detected 
early being very significant at the end point, with a dose-dependent reduction in tumor 
mass. Histological studies revealed a specific reduction in tumor parenchyma and in 
specific tumor cell markers. These results represent an important step toward the 
rational development of an efficient, safe and more specialized gene-delivery device for 
tumor therapy. 
*Abstract
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1. INTRODUCTION 
Breast cancer is the most commonly occurring cancer diagnosed in women in 
Western societies, with men also being affected but to a lesser extent. Despite 
considerable recent progress in the early detection of breast cancer and the improved 
treatments, such as immunotherapy, chemotherapy, radiotherapy or endocrine therapy 
available, which have been shown to improve the clinical outcome, the cure rate has not 
increased and mastectomy is often also required, thus causing significant psychological 
sequelae in affected patients [1]. Moreover, chemotherapy and radiotherapy treatments 
are not cancer-specific and also present side effects that often imply a worsened 
condition and increased patient discomfort. This situation suggests the need to develop 
new alternative therapeutic approaches, such as gene therapy, that may prove useful 
alone, or in combination with existing ones, as regards focusing treatment only at the 
site of action to ensure increased effectiveness, reduce the treatment dose, and decrease 
adverse systemic side effects [2, 3].  In addition, gene therapy offers the possibility of 
treatments that eradicate tumors without damaging normal tissue [4]. Different 
approaches have been developed in gene therapy to treat breast cancer, including the 
transfer of toxic or pro-apoptotic genes. To date, most research into suicide gene 
*Manuscript
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therapy in breast cancer has focused on the use of viral vectors [5-9], mainly due to their 
higher transfection levels. Thus, herpes simplex virus thymidine kinase (HSVtk) gene 
has been delivered by an adenovirus in combination with ganciclovir as the first and 
most common strategy used in experimental and clinical studies of suicide gene therapy 
[10, 11]. However, recent promising advances in the field of non-viral vectors represent 
a real alternative in terms of safety and cost-effectiveness [12, 13]. Several non-viral 
systems have been applied for suicide gene therapy purposes as well to carry therapeutic 
plasmids controlled by tumor-specific promoters. The latter allow the gene of interest to 
be selectively expressed in cancer cells without damaging healthy ones [14]. Human 
epidermal growth factor receptor 2 (HER-2) [15], survivin [16] or mucin-1 (MUC-1) 
[17] promoters have been used to control the expression of suicide genes. MUC1 is a 
transmembrane glycoprotein which is overexpressed and aberrantly glycosylated in 
many epithelial cancers, such as pancreas, lung, colon, prostate and breast cancers 
[18,19]. Cancer-associated post-translational glycosylation pattern determines the 
incomplete glycosylation of MUC1 forms. Hypoglycosylated MUC1 forms are 
expressed only in cancer cells and therefore, they are of great interest as immunotherapy 
targets and prognostic biomarkers. For instance, the MUC1 promoter was shown to 
control expression of the targeted truncated proapoptotic tBid gene delivered by 
poly(ethylene glycol) (PEG)-polyethylenimine (PEI)-based polyplexes in breast cancer 
cells [17]. In addition, tumor-specific promoters provide a safe and effective strategy for 
designing gene-therapy systems that can be adapted for use with various tumors or 
delivery systems. To date, ELRs and other polymers widely used as non-viral vectors, 
such as poly-lysine (PLL), polyethylenimine (PEI), polyethyleneglycol (PEG), chitosan, 
poly(lactic-co-glycolic acid) (PLGA), or poly(2-dimethylaminoethyl methacrylate) 
(pDMAEMA) [20], have found increasing applications in biomedicine due their 
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inherent biocompatibility and smart properties [21-29]. A previous study showed the 
ability of ELRs joined to functional peptides to be used as delivery vectors with no 
cellular effects in vitro [30]. Further research with ELR-based polyplexes coated with 
MUC1-specific aptamers opened the way to the use of ELRs part of a breast cancer 
selective vector [31]. MUC1, which is known to be aberrantly overexpressed in about 
90% of breast cancer cells, was used as targeting glycoprotein by th 5TR1 aptamer [32]. 
The ribosome inactivating protein (RIP) type I Pokeweed antiviral protein (PAP-S) has 
also been tested as a suicide gene and found to induce higher cell death in target 
transfected cells in comparison with controls [31]. 
Conversely, it is important to note that type 1 RIPs are not as toxic as type 2 RIPs 
since they are unable to cross the cell membrane on their own. Despite the high amounts 
of toxin produced, death events were only induced in transfected cells, in other words 
there is a greater possibility of generating an immune response and a dependence on the 
transfection efficiency, thereby limiting their potential of suicide therapy. In order to 
increase the harmful potency of the suicide gene, the type II RIP ricin, which is 
produced naturally by Ricinus communis, is proposed in the present study [33, 34]. 
Ricin is synthesized as preproricin, which comprises a 24-amino-acid N-terminal signal 
sequence followed by the A chain, which is attached to the B chain by a 12 amino-acid 
linker [35]. During synthesis, the signal sequence is removed to generate the mature 
protein, in which chains A (N-glycosidase activity) and B (lectin which binds to β-1,4-
linked galactose residues) are bound by a disulfide linkage. When chain A is bound to 
chain B, the latter allows rapid internalization into the cell and translocation of the 
catalytic chain to cytoplasm, thus triggering inactivation of the 28S RNA in the 60S 
ribosomal subunit [36] and inhibiting protein synthesis, thereby leading to cell death. 
Ricin-induced apoptosis mediated by different caspases, depending on the cell type, has 
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been also described in in vitro studies [37-39]. Most of the research into ricin has been 
performed in cancer immunotherapy using chain A or blocking the galactose-binding 
sites from chain B [40]. The results showed the ability of these immunotoxins to kill 
human myeloma, lymphoma and lung cancer cells, amongst others [41-44]. A phase I 
clinical trial with “Combotox”, which is a mixture of two immunotoxins prepared by 
coupling deglycosylated ricin A chain (dgRTA) to monoclonal antibodies targeting 
CD22 (RFB4-dgRTA) and CD19 (HD37-dgRTA), showed complete remission in three 
of 17 patients with acute lymphoblastic leukaemia (ALL) [45, 46]. However, the whole 
ricin protein has not been used in vivo due to the high cytotoxicity levels induced by 
ricin holotoxin. Compared with conventional agents, ricin has some features, such as a 
potent action, an inability to induce resistance and the fact that it can act on both 
dividing and non-dividing cells that make it attractive, although side effects such as 
vascular leak syndrome or demyelination, have to be controlled. To date, no suicide 
therapy studies using ricin gene to combat breast cancer have been conducted.  
In this study we developed a complete delivery system comprising two elements, 
namely a transfection vector and therapeutic DNA content. To obtain the transfection 
vector, the polycationic ELR (VPGKG)x72 [31] was covalently linked to the 5TR1 
aptamer by means of click chemistry [47]. This aptamer is known to be directed towards 
the underglycosylated variable number tandem repeat (VNTR) region of MUC1, which 
is rich in serine, proline and threonine, and has previously been designed and used for 
molecular targeting [48, 49]. Moreover, the therapeutic DNA was designed to contain 
the MUC1 tumor specific promoter (hMUC1 promoter) and ricin gene modified with 
the preprotrypsin leader sequence. The use of preprotrypsin leader should allow the 
secretion of mature ricin and its diffusion from the transfected tumor to neighboring 
cells, thus triggering the bystander effect [50]. Both the vector and therapeutic DNA 
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constitute a double safety lock device controlled by the presence of MUC1 on the cell 
surface and applied to directed suicide therapy for breast cancer in vitro and in vivo. 
This article reports the effective inhibition of tumor growth in mice treated with ELR-
5TR1 pDhMUC1-ricin polyplexes.  
 
2. MATERIALS AND METHODS  
2.1. Chemicals, proteins and cell lines 
Unless otherwise indicated, all chemicals were purchased from Sigma Aldrich 
(Germany). Restriction and modification enzymes for DNA cloning were purchased 
from Thermo Fisher (USA). TNHS-PEG-cyclooctyne was purchased from SynAffix 
(ref. SX-A1006, Netherlands). The preproricin gene was purchased from NZYTECH 
(Portugal) and the pDrive5Lucia-hMUC1 plasmid, abbreviated as pDhMUC1-
luciferase, from Invivogen (USA). Paraformaldehyde and Turbofect were purchased 
from Sigma Aldrich (Germany). 
The fluorescent labelled aptamers 5TR1-Cy5.5 (5’Cy.5.5-
GAAGTGAAAATGACAGAACACAACA-Azide’3) and 5TR1 (5’-
GAAGTGAAAATGACAGAACACAACA-Azide’3) were purchased from Metabion 
(Germany). Reagents for histological analysis were purchased from Sigma and 
antibodies were purchased from Abcam (UK), unless otherwise indicated. 
XL-1 Blue competent cells (ref. 200249) were purchased from Stratagene (USA). 
Human foreskin fibroblasts HFF-1 (ref. SCRC-1041) and human breast 
adenocarcinoma SKBR3 cells (ref. HTB-30
™
) were purchased from the American 
Type Culture Collection (ATCC, USA). Human breast cancer MCF-7 (ref. 86012803) 
and liver hepatocellular carcinoma HepG2 (ref 85011430) cell lines were supplied by 
Sigma-Aldrich. Basal medium Dulbecco’s modified Eagle’s medium (DMEM), 
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Eagle’s minimum essential medium (EMEM), McCoy’s 5A medium, 2mM glutamine, 
and 1% NEAA, fetal bovine serum (FBS), penicillin streptomycin solution, trypsin-
EDTA, DPBS, LIVE/DEAD® Viability/Cytotoxicity Kit for mammalian cells, and 
Alamar Blue® were supplied by Invitrogen (USA).  
2.2. Design and cloning of pDhMUC1-ricin plasmid  
The therapeutic plasmid pDhMUC1-ricin was obtained by replacing the luciferase 
gene with the modified ricin gene in the original pDhMUC1-luciferase plasmid. The 
ricin gene was cloned downstream of the preprotrypsin leader-ricin gene using NcoI and 
NheI restriction enzymes. The XL-1 Blue competent Escherichia coli strain was 
transformed with the recombinant plasmid and grown in agar medium containing the 
selection agent zeocin (Invivogen, USA). The sequence correctness of the recombinant 
vector was confirmed by diagnostic digestion using the EcoRI restriction enzyme and 
followed by DNA sequencing. All plasmid DNAs (pDNA) were purified using the 
Endofree ® Plasmid Maxi Kit (Qiagen, Germany).  
2.3. Synthesis and characterization of the transfection vector (ELR-5TR1)  
2.3.1. Preparation of ELR-PEG-cyclooctyne  
ELRx72 (abbreviated as ELR) was biosynthesized as described by Piña et al. [31]. 
Thus, 1 equivalent of ELR (20 mg/mL) dissolved in dimethyl sulfoxide (DMSO) was 
mixed with 0.46 equivalents of NHS-PEG-cyclooctyne (3 mg/mL) in DMSO under a 
nitrogen atmosphere at 37ºC. The mixture was stirred overnight at 25ºC. After this time 
30 mL of fresh ultrapure water was added to the crude mixture, dialyzed against water 
and lyophilized. The incorporation of PEG into the ELR as ELR-PEG-cyclooctyne was 
evaluated by nuclear magnetic resonance (NMR). 
2.3.2. Preparation of ELR-5TR1 
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1.1 equivalents of azide-5TR1 aptamer or the fluorescent version azide-5TR1-
Cy5.5 (10 mg/mL) were mixed with one equivalent of ELR-PEG-cyclooctyne (10 
mg/mL) previously dissolved in ultrapure water and the resulting mixture incubated 
at 4ºC for 48 hours. After this time the product was dialyzed against ultrapure water 
at 4ºC and lyophilized. Incorporation of the aptamer was corroborated by gel 
retardation assay and quantified by absorbance spectrophotometry (at 260 nm) and 
flow cytometry.  
2.3.2.1. ELR-5TR1 characterization: Electrophoretic mobility shift assays 
(EMSA) and spectrophotometry assay 
ELR-5TR1 was dissolved in ultrapure water at 1 mg/mL and treated with 10% 
SDS, then submitted to electrophoresis on 3% MetaPhor
TM
 agarose (Lonza, USA) gel 
in 1xTAE buffer at 6 V/cm, staining with SimplySafe
TM
 (EURx, Poland). 5TR1 
aptamer was used as control. The conjugated oligonucleotide was visualized by 
exposure to UV light in a transilluminator (Vilber, Germany). ELR-5TR1 was 
dissolved in ultrapure water at 1 mg/mL and absorbance was measured at 260 nm 
using a Nanodrop 2000 instrument (Thermo scientific).  
2.4. Preparation of polyplexes 
Polyplexes comprising ELR-5TR1-pDNA were formed at a 50/1/4 ratio in 
aqueous solution (N/P/Papt, where N corresponds to the number of amine groups from 
the polymer, P to the phosphate groups from the plasmid DNA and Papt to the 
phosphate groups from the aptamer). Adjustment to the 50/1/4 ratio was achieved by 
mixing both ELR-5TR1 and free ELR. To prepare the polyplexes, ELR-5TR1 
biopolymer was previously dissolved overnight in 5% glucose (w/v) solution to a 
concentration of 1 mg/mL at 4°C. Complexes were formed by mixing the pDNA with 
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the ELR solution. The mixture was vortexed vigorously at 25 °C for 1 minute and 
then incubated at 25 °C for 30 minutes to allow polyplex formation.  
2.4.1. Polyplex characterization by flow cytometry 
Polyplexes with the fluorescent labelled aptamer 5TR1-Cy5.5 were formed and 
characterized by flow cytometry. ELR-5TR1-Cy5.5-pDNA polyplexes were formed in 
aqueous solution. The incorporation of 5TR1-Cy5.5 was evaluated using a Gallios 
flow cytometer (Beckman Coulter, USA) with the side-scatter outcome set to 
logarithmic. A flow rate of 75,000 events/s was recorded, with a total of 100,000 
events per measurement. Data were analyzed using Flowing Software. 
2.5. Physical characterization of polyplexes 
2.5.1. Particle size and zeta potential 
The particle size and zeta potential of ELR-5TR1-pDNA were measured using a 
Zetasizer NanoZs (Malvern) at 37°C. The mean Z-average (nm), polydispersity index 
(PdI) and zeta potential (mV) were used for data analysis.  
2.5.2. Transmission electron microscopy (TEM) 
TEM measurements were performed using a JEOL JEM-1230 electron 
microscope operating at 120 kV. The polyplex solution was dropped onto carbon-coated 
copper grids and images recorded after drying for 4 hours at 37 °C. 
2.6. Cell culture 
Human breast cancer (MCF-7) and liver hepatocellular carcinoma (HepG2) cell 
lines were maintained in EMEM supplemented with 10% FBS, 2mM glutamine, 1% 
NEAA. Human fibroblasts (HFF-1) were cultured in DMEM supplemented with 15% 
FBS. Human breast cancer (SKBR3) cells were cultured in McCoy’s 5A medium 
supplemented with 10% FBS. All complete media were supplemented with 100 U∙mL-1 
penicillin and 0.1 mg∙mL-1 streptomycin. Cells were cultured in a humidified 5% CO2 
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atmosphere at 37 °C, replacing the medium every two days. Cell lines were harvested at 
70–80% confluence and were used between passages 2 and 6.  
2.7. Transfection assays 
2.7.1. Cell viability assay of polyplexes functionalized with aptamers 
ELR-5TR1-pDNA polyplexes containing pCMV-Gaussia Luciferase plasmid 
were formed and their effect on cell viability assessed. Thus, MCF-7 cells were plated 
at a cell density of 3x10
4
 cells per cm
2
 and incubated overnight. They were then 
incubated with the ELR-5TR1-pDNA polyplexes formed with 1.7 nM pCMV-Gaussia 
Luciferase plasmid or 1 µL Turbofect, used as reference transfection polymer, under the 
same conditions for 5 hours in antibiotic- and FBS-free culture medium. After this time, 
the medium was replaced with complete medium and the cells were incubated for a 
further 43 h at 37 °C. Cells were visualized by contrast phase microscopy using a Leica 
SP5 confocal microscope (Leica Microsystems). 
2.7.2. Analysis of transfection efficiency by Luciferase expression 
A total of 3x10
4
 cells per cm
2
 of MCF-7, SKBR3 or HepG2 and 1x10
4
 cells per 
cm
2
 of HFF-1, in order to have the same level of confluence, were seeded onto 96-well 
plates and grown overnight. The cells were then incubated in an antibiotic- and serum-
free medium for 5 h in the presence of the polyplexes (ELR-5TR1-pDhMUC1- 
luciferase); 1 µL of Turbofect and the nude plasmid DNA were used as control. The 
medium was then replaced by serum-containing medium and the cells cultured for a 
further 43 h. At this point, a 20µL aliquot was removed from the culture medium and 
mixed with the luciferase substrate (Thermo Scientific, USA). The light produced was 
measured using a SpectraMax L luminometer (Molecular Devices, USA). The protein 
content of the lysate was determined by a Bradford assay using a SpectraMax M2e 
10 
 
microplate reader (Molecular Devices, USA). Luciferase expression is reported as 
relative light units (RLU) per mg total protein. 
2.7.3. Cell transfection assays by cellular viability  
96-Well plates seeded with 3x10
4
 cells per cm
2
 of MCF-7, or 1x10
4
 cells per cm
2
 
of HFF-1, were incubated at 37 °C/5% CO2 overnight prior to treatment with the 
polyplex. For these experiments, ELR-5TR1-pDhMUC1-ricin polyplexes containing 
different amounts of pDNA (1.7x10
-3
, 1.7x10
-2
, 1.7x10
-1
 and 1.7 nM) were formed and 
incubated with cells in an antibiotic- and serum-free medium at 37 °C/5% CO2 for 5 h. 
After this time, the medium was replaced with fresh complete medium and the cells 
cultured for a further 43 h prior to analysis. Cell viability was quantified using the 
Alamar Blue® assay following the manufacturer’s instructions and the fluorescence 
intensity (F.I.) of test samples and controls measured at an emission wavelength of 590 
nm after excitation at 560 nm using a SpectraMax M2e microplate reader (Molecular 
Devices, USA). Cell viability was calculated as: 
 % Cell viability = 100x (F.I. polyplex-treated cells/F.I. polymer-treated cells) 
CC50, defined as the cytotoxic drug concentration lethal for 50% of cells, was 
calculated and considered as the pDhMUC1-ricin concentration at which 50% cell 
death was observed. 
2.8. In vivo assays 
The in vivo experimental protocols were performed in accordance with the 
recommendations of the Guideline for the Care and Use of Laboratory Animals and 
approved by the Ethics Committee from the University of Valladolid (Spain). 
Female Balb/c nu/nu mice aged 5-7 weeks and weighing about 17 g were purchased 
from Janvier Labs (France). 17β Estradiol pellets weighing 0.72 mg (Innovative 
Research of America, USA) were implanted in the loose skin of the mouse’s mid-
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scapular region after anesthetization with Vetflurane (Virbac, UK). Two days after 
implantation of the pellet, mice received a single subcutaneous xenograft injection 
of 1.0 × 10
6
 MCF-7 cells suspended in 100 µL of 1:1 minimum medium (Geltrex™ 
reduced growth factor basement membrane matrix, Gibco) into the right abdominal 
flank. Both tumor growth, measured by a caliper, and body weight were monitored 
daily throughout the experiment (23 days). Tumor volume was calculated using the 
formula 0.523 LW
2
 where L is the length and W the width of the tumor in mm. After 
seven days, once the mean tumor volume had reached 50 mm
3
, all mice were 
randomly separated into five statistical groups of eight animals each: group 1, placebo 
(5% glucose), group 2, negative control (70nM ELR-5TR1-pDhMUC1-luciferase, no 
therapeutic pDNA), and three groups treated with different doses of therapeutic plasmid 
ELR-5TR1-pDhMUC1-ricin (1.7, 17 and 70 nM). All doses were prepared with ELR-
5TR1-pDNA at a final volume of 100 µL in 5% glucose. Furthermore, a drug safety 
control group containing mice with no tumors treated with the maximum dose of ELR-
5TR1-pDhMUC1-ricin (70 nM) and another drug safety control group (sham control) 
corresponding to animals injected with Geltrex matrix lacking tumor cells were 
included. Administration of the first treatment dose was considered as day 0. All 
treatments were administered peritumorally on days 0, 2, 4, 6 and 9. At day 23, the 
animals were sacrificed by manual cervical dislocation as indicated in the relevant 
regulations. After necropsy, tumors were extracted, weighed and properly stored.  
2.9. Tissue Processing, histological staining and immunohistochemical assays 
Tumors were fixed with 4% paraformaldehyde and embedded in paraffin. The 
paraffin tumor blocks were then serially sectioned into sections with a thickness of 5 
µm and transferred onto glass microscopy slides. Histological sections were 
subsequently de-paraffinized and re-hydrated for hematoxylin-eosin (H&E), Picro 
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Sirius and immunohistochemistry (IHC) staining. For IHC analysis of the sections, 
antigen retrieval was performed by incubation in 10 mM sodium citrate buffer pH 6 at 
95°C for 20 min, then cooling for 20 min at room temperature. The sections were then 
washed and incubated in blocking solution (PBS supplemented with 2% BSA and 10% 
goat serum Invitrogen, ref 50-197Z) for 30 min at room temperature. The samples were 
incubated overnight at 4°C with the following primary antibodies: anti-MUC1 (1:100) 
(ref ab15481), anti-ki67 (1:500) (ref ab15580) and anti-CD31 (1:50) (ref ab28364) in 
antibody diluent (Dako). The slides were subsequently washed with PBS and then 
incubated with fluorescent secondary antibody Goat Anti-Rabbit (ref ab150077) at a 
1:500 dilution in blocking buffer for 40 min at room temperature. Cell nuclei were 
counterstained with 4′-6-diamidino-2-phenylindole (DAPI) stain. 
2.10. Statistical analysis 
Results were expressed as mean ± SD. The statistical significance of the results 
was analyzed using SPSS (version 20). The RLU/mg of ELR-pDNA polyplexes in 
transfection was analyzed using Student’s t-test. All results with p<0.05 for three 
independent experiments were considered to be statistically significant. In animal 
studies, differences between the mean tumor masses on the last day of treatment were 
compared using a one-way analysis of variance ANOVA (ANOVA, α = 0.05, p < 0.05). 
Following ANOVA, a Tukey-Kramer post-hoc analysis was performed to compare the 
mean of one group with the mean of another group. A p value of less than 0.05 was 
consider to be statistically significant and is indicated in the corresponding figures with 
an asterisk, as reported in the results.  
3. RESULTS 
3.1. Design of pDhMUC1-ricin 
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The therapeutic plasmid DNA was based on the commercial pDhMUC1-
luciferase plasmid, with the luciferase gene being replaced by the modified ricin gene 
containing the preprotrypsin leader (1698bp) in order to avoid difficulties in post-
translational modifications of ricin, thus creating a new pDhMUC1-ricin (4403bp) 
(Figure S1 and S2). However, since N-t modifications have been shown to have 
important effects on protein expression, a small sequence of five amino acids from the 
original leader sequence was conserved to ensure expression of the holotoxin in 
mammalian cells. Thus, the luciferase gene pDhMUC1 (2705 bp) was excised from the 
plasmid using NheI and NcoI restriction enzymes (Figure S2A). In a parallel reaction, 
the inserted modified ricin gene (1698 bp) was released from the preproricin plasmid by 
PscI and NheI digestion. After purification of the plasmid and insert, a ligation reaction 
led to creation of the new pDhMUC1-ricin. Cloning was confirmed by analyzing 
diagnostic digestion by EcoRI by agarose electrophoresis, which corroborated the 
plasmid construct size of 4403 bp, and by DNA sequencing, which confirmed the 
correctness of the sequence (Figure S2B). This pDhMUC1-ricin was used as therapeutic 
plasmid in suicide gene therapy experiments. 
3.2 Synthesis and characterization of the ELR-5TR1 
The ELR polymer corresponding to the amino acid sequence MESLLP 
(VPGKG)72V was produced as described previously [31]. Endotoxins were eliminated 
and their levels evaluated, and were always found to be <1 EU/mg. Functionalization of 
the ELR with PEG-cyclooctyne was obtained via an amidation reaction between the  
amine group from the lysine present in one equivalent of ELR and 0.46 equivalents of 
the reactant NHS-cyclooctyne-PEG, which carries an activated carboxylic group as the 
N-succinimidyl ester (Figure S3). After lyophilization, a white spongy solid was 
obtained (92 mg, 2.83 µmol) in a chemical yield of 91.6%. Due to the high molecular 
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weight of the ELR (32 kDa) in comparison with the low conversion required (2.1 mol of 
ELRx72:1 mol of PEG-cyclooctyne), which includes 217 Da for the PEG-cyclooctyne, 
it was not possible to quantify the amount of NHS-cyclooctyne-PEG incorporated using 
mass spectrometry as the weight of the latter falls within the margin of experimental 
error (0.5%).  In the 
1
H NMR spectrum, the appearance of new signals characteristic of 
the cyclooctyne derivative at 7.0 ppm (H-N from carbamate), 4.0 ppm (methylene group 
adjacent to carbamate and cyclopropyl group) and 2.9 ppm (methylene groups adjacent 
to the nitrogen of lysines forming the new amide bond) was observed (Figure S4). 
These signals allowed us to deduce that the PEG-cyclooctyne group was present along 
the peptide chain. Although the integration of these peaks was not sufficiently clear, it 
was possible to assign a conversion degree of 68% for the lysines based on the 7.0 ppm 
peak (this peak would integrate for 1.37H for 100% conversion, therefore the 0.93H 
obtained suggests a conversion of 68%). 
Once the PEG had been bound to the ELR, a click reaction was performed 
between the ELR-PEG and azide-5TR1 with or without Cy5 (Figure S3). The 5TR1 
aptamer labeled with Cy5 was used in a parallel reaction under the same conditions in 
order to verify the incorporation of aptamers into the ELR-PEG-cyclooctyne to form a 
polyplex by fluorescence and detect them by flow cytometry. For the click chemistry 
reaction, 1.1 equivalents of azide-5TR1 or azide-5TR1-Cy5 was mixed with 1 
equivalent of modified ELR-PEG-cyclooctyne in aqueous solution at 4ºC, as described 
in section 2.3.2. Incorporation of the 5TR1 aptamer was corroborated by gel retardation 
assay (EMSA), absorbance and flow cytometry (Figure S5, S6A and B). A solution of 
ELR-5TR1 biopolymer containing about 150 ng 5TR1 with 10% SDS was loaded onto 
a 3% Methaphor gel. As shown in Figure S5, the 5TR1 aptamer contained in the 
ELR-5TR1 construct was present and retained on the agarose gel, whereas 5TR1 
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alone was able to migrate freely along the gel. In addition, the concentration of 
5TR1 in the ELR-5TR1 biopolymer was estimated by measuring the absorbance at 
260 nm. As shown in Figure S6A, the absorbance of ELR-PEG-cyclooctyne used as 
control was almost zero due to the monotonous composition of the ELR, whereas it 
was around 0.62 AU260 for ELR-PEG-5TR1, thus allowing us to quantify the amount 
of DNA. After the click reaction, 0.1 mmol of 5TR1 was coupled to 0.4 mmol of 
ELR-PEG-cyclooctyne with 92% substitution.  
Once the biopolymer had been lyophilized, fluorescent polyplexes comprising 
ELR-5TR1-Cy5 and pDNA were formed and analyzed by flow cytometry. As shown 
in Figure S6B, a homogeneous population corresponding to these polyplexes was 
obsrved when side versus forward scatter was plotted. In addition, when the 
intensity count was plotted as a function of FL6 channel, a 100% labeling was 
observed for polyplexes comprising Cy5-labeled 5TR1 when compared with the 
polyplexes lacking the aptamer (Figure S6C) used as control. Hence, flow cytometry 
analysis showed both incorporation of the labeled 5TR1 aptamer into the ELR-PEG-
cyclooctyne and the ability of this ELR-5TR1 biopolymer to form polyplexes in the 
presence of plasmid DNA.  
3.3. Polyplex size, zeta potential and TEM 
The size of the ELR-5TR1-pDNA polyplexes was determined by dynamic light 
scattering (DLS) in 5% glucose solution. The results showed a homogeneous 
polyplex population with a size of 146.7±7.5 nm (Figure 1A) and a PDI of 0.13. The 
formation of spherical nanoparticles with a size of 135.5±20 nm was corroborated by 
TEM microscopy (Figure 1B), with all polyplexes showing a rounded shape. In 
addition, the zeta potential was measured, with the value for ELR-5TR1-pDNA 
16 
 
polyplexes beings +35.1 mV, which increased to +40 mV in the absence of 5TR1, 
thus corroborating the presence of the conjugated aptamer. 
3.4. In vitro transfection assays  
The lack of cellular toxicity of the ELR has been reported previously [30]. 
Despite this, an additional comparison with a commercial non-viral gene-delivery 
system (Turbofect) was performed (Figure S7) and the biocompatibility of the ELR-
5TR1 construct for the target MCF-7 cells was confirmed. In order to use this ELR-
5TR1 as a delivery vector, its transfection ability was tested with pDhMUC1-luciferase. 
Thus, the tumor cell lines (MCF-7 MUC1 (+), SKBR3 MUC1 (+), HepG2 MUC1 (-)) 
and the primary cell line (HFF-1 MUC1 (-)) were transfected with the ELR-5TR1-
pDhMUC1-luciferase polyplexes. As shown in Figure 2, luciferase expression did not 
show any significant variation when compared with cells treated with pDhMUC1-
luciferase nude plasmid or polyplexes comprising ELR and ELR-5TR1 in HepG2 and 
HFF-1 cells. In contrast, a significant increase was observed for SKBR3 treated with 
ELR-5TR1 polyplexes when compared with those incubated with ELR polyplexes. The 
highest significant increase in transfection (nearly sixfold) was observed for MCF-7 
treated with ELR-5TR1 polyplexes when compared with polyplexes lacking the 
aptamer. The expression level of luciferase in MCF-7 cells was also found to be 
significantly higher than when using Turbofect.  
  
 
3.5. In vitro specific cytotoxicity of therapeutic polyplexes 
In order to evaluate the effect of pDhMUC1-ricin plasmid on human breast cancer 
MCF-7 and human foreskin fibroblast HFF1 transfected cells, a cytotoxicity assay was 
performed using non-transfected cells as control, as indicated in the Materials and 
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Methods section (2.7.3). Four different plasmid concentrations were tested and, as 
shown in Figure 3, no cytotoxic effects were observed for the primary fibroblast cell 
cultures at any concentration. In contrast, dose-dependent cytotoxicity was observed for 
MCF-7 cells at a plasmid concentration of 1.7x10
-2
 nM. CC50, which is defined as the 
cytotoxic concentration of drug lethal for 50% of cells, was calculated and found to be 
0.28 nM. This value was therefore used for the following in vivo experiments. 
3.6. Suicide therapy in vivo 
To confirm whether the observed in vitro anti-tumor therapeutic potency of 
pDhMUC1-ricin polyplexes translates to the in vivo scenario, they were tested in a 
human breast xenograft transplanted into a Balb/c nude mouse model. Human breast 
cancer tumors were induced in estradiol-supplemented female Balb/c nude mice by 
subcutaneous injection of MCF-7 cells into a commercial matrix-forming gel. Seven 
days after the xenograft injection, animals with an average palpable tumor size of 50 
mm
3
, were divided into groups and treated with two negative control treatments and 
three different concentrations (1.7, 17 and 70 nM (0.027, 0.27 and 1.1 µg plasmid/g 
mouse)) of therapeutic pDhMUC1-ricin. Treatments were administered a further four 
times, as indicated by the arrows in Figure 5 A) Tumor volumes were estimated daily 
using a caliper in double-blind measurements. 
Our results showed significant differences in tumor volume growth evolution 
between both the placebo and negative control (pDhMU1-luciferase) and the treated 
groups (Figure 4A). This difference was maintained over time, reaching very significant 
values from day 10 (p<0.05) to the end of the experiment (p<0.001; day 23 after first 
injection). At this time, placebo and negative control tumors reached an average volume 
of 273 ± 90.12 and 233 ± 122.97 mm
3
, respectively, whereas the 70 and 17 nM 
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treatment groups exhibited tumors of around 44 ± 32.84 mm
3
, thus representing a 
reduction of more than than 80%.  
At the end of experiment, the tumors were extracted and weighed. The average 
tumor weight for the treated groups was 55.42 ± 21.67, 60 ± 35.21 and 85.12 ± 55.44 
mg for 70, 17 and 1.7 nM doses, respectively, compared with 145.2 ± 19.61 mg for the 
placebo group and 142.67 ± 57 mg for the negative control group. The results are 
plotted in Figure 4B and show significant differences between negative controls and the 
70 nM and 17 nM treatment groups. Despite this, the group treated with the 1.7 nM 
dose did not show any significant differences with respect to the placebo and negative 
control groups, thus suggesting that the treatment exhibits a dose-dependent pattern, 
which contrasts with the tumor volume results, where all doses produced a similar 
reduction (Figure 4). In addition, mice showed no adverse side effects, as reflected in 
the normal weight gain throughout whole experiment, the absence of anomalous 
behavior in all groups (Figure S8), and the lack of toxic symptoms in the drug safety 
control group.  
A qualitative characterization of the tumors was carried out using both 
histological and immunohistochemical techniques. Thus, hematoxylin/eosin (H&E) 
and picro sirius staining (Figures 5 and 6, respectively) provided general information 
on the composition of the tumor. 
Histological sections of representative tumors from the placebo and treated 
groups are shown in Figure 5. An abnormal solid mass comprising a tumor nucleus 
surrounded by connective tissue and vessels was found in almost all cases. This zone 
is more extended and shows a high cell density, as demonstrated by the more intense 
hematoxylin staining in the control tumors (Fig. 5A) compared to the treated ones. 
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The latter shrunk in a dose-dependent manner, and some tumors from the group 
treated with the highest dose showed a lower cell density (Fig. 5B). Interestingly, no 
substantial variation in the area of accessory tumor tissues (vascular and connective 
tissue) was observed in any of the groups analyzed. As such, the considerable 
difference in size between the tumors from the treated and nontreated groups is due to 
the extension of the inner mass. These results were also corroborated by Picro Sirius 
staining (figure 6), which enabled us to identify connective tissue (collagen I and III 
fibers stained red, cytoplasm and muscle fiber stained orange/yellow). In tumors 
from the group treated with the highest dose (Fig. 6B), the inner tumor mass looks 
smaller and richer in collagen than the control tumor group (Fig. 6A). 
A molecular characterization of the tumor was carried out by 
immunohistochemistry, evaluating the presence of residual human MCF7 tumor cells 
by immunostaining against MUC1 antigen, which is overexpressed in the MCF7 breast 
carcinoma cell line (Fig. 7). All tumors containing a compact inner tumor mass showed 
in this zone an intense positive immunostaining with anti-MUC1, with this positivity 
being evident in the inner tumor mass of tumors from the placebo group (Fig 7A). In 
contrast, tumors treated with ricin polyplexes 70 nM showed very low or negative 
immunostaining (Fig. 7B). 
Immunostaining against MUC1 antigen confirmed the specificity of the treatment 
by allowing a significant reduction in the number of target tumor cells. As such, 
administration of more doses of the ricin polyplexes could eliminate all residual tumor 
cells. 
Another breast cancer prognostic parameter is cell proliferation rate, as 
measured using the Ki67 antibody, which recognizes a nuclear antigen specifically 
expressed in proliferating cells. Cell proliferation was found to be lower in all 
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treated tumor groups compared with controls, and was undetectable in some tumors 
from the group treated with the highest dose (Figure S9, S10).  
Tumor vessels were labelled by CD31 immunostaining (Fig. 7), with positive 
staining being observed in the area surrounding the tumor nucleus and inside the 
tumor mass for both placebo (A) and ricin polyplex (B) groups. The number of 
blood vessels (as measured by CD31 staining) did not decrease as significantly post-
treatment compared with control tumors. However, the latter showed a more 
infiltrative profile, with vessels penetrating to the most central part of the tumor 
nucleus.  
 
4. DISCUSSION 
Previous studies by our group have demonstrated the ability of polyplexes 
comprising ELR, absorbed MUC1 aptamers, and a therapeutic plasmid containing 
the PAP-S gene to target breast cancer cells and cause cellular death [31]. This study 
extends our work with this system and uses it to create a double safety-lock 
regulated device controlled by the presence of MUC1. Moreover, the main objective 
of this study is to destroy transfected and neighboring breast cancer cells using a 
modified ricin, thereby increasing the potential harm without damaging nontumor cells 
both in vitro and in vivo. The first lock arises due to the presence of the 5TR1 
aptamer, which was attached to the ELR via a PEG spacer in order to facilitate 
binding between the aptamer and its target. PEG has commonly been used as spacer 
in targeted drug-delivery systems due to its high aqueous solubility, lack of toxicity 
and immunogenicity, and high flexibility, which allows PEGylation with no steric 
hindrance [51, 52]. The 5TR1 aptamer binds to the aberrantly hypoglycosilated 
MUC1 located on the breast cancer-cell surface. The second lock corresponds to the 
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hMUC1 promoter, which ensures expression of the cytotoxic ricin with the 
preprotrypsin leader only in MUC1 overexpressing cells [53, 54].  
Functionalization of ELR with the 5TR1 aptamer, as shown in Figure S4, is 
possible due to the presence of SDS, which promotes the cleavage of hydrogen 
bonds in the secondary protein structure but not covalent bonds. Since our previous 
experience with click chemistry showed high levels of substitution [47], we can 
assume that most of the 5TR1 in ELR-PEG is linked to the polymer. Indeed, the 
concentration of 5TR1 in the biopolymer was quantified by measuring the 
absorbance at 260 nm, which allowed us to confirm a chemical yield of about 92% 
(Figure S5A). A retardation assay and spectrophotometry showed the presence of 
5TR1 in the ELR-PEG but were unable to corroborate the presence of 5TR1 in their 
functional conformation as a polyplex. To that end, labeled 5TR1-Cy5 was used in a 
parallel click reaction as described previously. Subsequent flow cytometry data 
showed that 100% of polyplexes comprising ELR-PEG-5TR1-pDNA were labeled 
with Cy5 (Figure S5B), thus confirming the presence of the aptamer in every 
polyplex and the ability of ELR-PEG-5TR1 to form such structures in the presence 
of pDNA.  
It has been widely reported that particle size has an effect on the internalization 
pathway. Thus, particles with a size of about 200 nm are known to be internalized via 
the endocytosis pathway, which may be beneficial for rapid entry into cells. In contrast,  
particles up to 10 µm gain cellular entry via phagocytosis [56, 57]. The polyplexes 
comprising ELR-PEG-5TR1-pDNA have a diameter of 190±7.5 nm (Figure 2A) and a 
PDI of 0.13, which, according to the literature, makes them suitable for cellular 
transfection. The low PDI and the zeta potential of +35.1mV provide the high 
stability required for gene-delivery purposes. Similar zeta potentials were obtained in 
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a previous study that gave satisfactory cell transfection results [30]. Additionally, a 
positive surface charge favors the internalization of polyplexes via the negatively 
charged plasma membrane [57]. Further characterization by TEM helped us to confirm 
that the complexes formed well-defined polyplexes with a homogenous size and shape 
(Figure S5B). The differences in size between the two measurements were attributed 
to the experimental conditions (polyplexes are hydrated for DLS and dried for 
TEM).  
The ideal gene-therapy device is one that attacks the tumor and stroma cells while 
maintaining healthy cells intact. MCF-7 human breast cancer cells have been shown to 
overexpress the MUC1 gene, which codifies for MUC1 glycoprotein [58]. Indeed, 
amplification of the MUC1 gene has been found in about 40% of breast cancers and 
significantly correlates with increases in MUC1 mRNA and protein levels [59]. The 
MUC1 C terminal (MUC1-C) subunit is involved in activating intracellular signaling 
pathways that result in activation of the MUC1 gene and its overexpression in breast 
cancer cells [60]. As such, we hypothesized that use of a plasmid containing the 
promoter, which is potentially activated in presence of MUC1, could allow genetic 
expression in the target human breast cancer MCF-7 cells only. Indeed, transfection 
assays with pDhMUC1-luciferase using three tumors and one primary cell line (Figure 
3) confirmed this hypothesis. In the case of HepG2 and HFF-1 MUC1 (-), luciferase 
expression did not show any variation when comparing cells treated with ELR-PEG-
5TR1 and ELR polyplexes. In contrast, a significant increase was observed in SKBR3 
cells MUC1 (+), although this increase was lower than that observed in MCF-7 cells. 
This difference between the two MUC1 (+) cell lines supports the lower expression of 
MUC1 in SKBR3 reported in the literature [61, 62]. Consequently, the most significant 
results with hMUC1 promoter were obtained for MCF-7 cells transfected with ELR-
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PEG-5TR1 polyplexes, with luciferase expression being nearly six times higher than for 
the control ELR lacking the aptamer, thereby confirming the specificity of the system. 
This finding correlates with our previous experience with cytomegalovirus promoter 
(CMV) and coated aptamers, which showed a similar increase in luciferase expression 
when the aptamer was present [30] and confirmed the initial hypothesis regarding the 
use of PEG as a spacer to improve binding to MUC1. In addition, is important to note 
that luciferase expression for MCF-7 cells with the ELR-PEG-5TR1 biopolymer was 
significantly higher than that obtained with the commercial product Turbofect lacking 
the aptamer used as reference polymer. 
Use of the ELR-PEG-5TR1-pDhMUC1-ricin system in suicide gene therapy was 
assessed in vitro. A cytotoxic effect was found in MCF-7 cells, with a CC50 of 0.28 
nM. In contrast, little or no effect was observed for HFF-1 cells, which are the most 
representative cell type in connective tissue [63] at all concentrations of the therapeutic 
device tested. This cytotoxic effect for pDhMUC1-ricin is in agreement with the 
expected toxic effects of ricin [64], thus suggesting the expression of functional and 
active ricin. Despite lacking CC50 data in MCF-7 cells, according to the literature, the 
CC50 for monkey kidney Vero cells incubated for 20 h with ricin is 7.6x10
-3
 nM [65], 
which contrasts with value of 0.67 pM for HeLa cells [66] and 0.1 nM when myeloid 
U937 cells when incubated for 12 h [67], thus showing that ricin cytotoxicity depends 
on the cell line, probably due to the different composition of glycoproteins on the 
cellular surface and the internalization pathway. This explains the cytotoxic effects 
observed after transfection with ELR-PEG-5TR1-pDhMUC1-ricin system. Thus, once 
an MCF-7 cell has been transfected, ricin is expressed as preproricin with the 
preprotrypsin leader sequence at N-terminal. Subsequently, by way of a protein 
maturation process [68, 69], mature ricin is secreted into the culture medium via an 
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exocytosis process, thus leading to the bystander effect. Some of this mature ricin re-
enters the endoplasmic reticulum, where RTA becomes active and translocates to the 
cytosol, subsequently exerting its action on the transfected cell. Once ricin has been 
secreted into the medium, Ricin B-chain (RTB) facilitates the translocation to 
neighboring cells, where RTA inhibits protein synthesis, thus leading to apoptosis and 
cell death [37, 38]. The CC50 value obtained was used in subsequent in vivo 
experiments, where the minimum concentration was above this value. 
The double safety-lock device ELR-PEG-5TR1-pDhMUC1-ricin allows control 
over the cellular entry and expression of ricin, which is important in vivo due to the 
potent action of this toxin. Treatment of mice bearing breast tumors with ELR-PEG-
5TR1-pDhMUC1-ricin decreased tumor volume growth by up to 85% in comparison 
with the placebo group (Figure 5A). In addition, significant differences were found 
between groups treated with the therapeutic agent up to day 10 after the first injection. 
Moreover, the in vivo cytotoxic effect at 1.7 nM correlates with the CC50 obtained at 
0.28 nM in vitro. Bearing in mind the change from a 2D culture to a 3D tumor, where 
cell accessibility is more difficult for this in vivo assay, at least six times more of the 
0.28 nM dose was administered in order to ensure the cytotoxicity of the system. 
Additionally, the reduction in tumor volume was confirmed by weighing the tumors 
post-necropsy which showed significant differences between placebo and negative 
control group (145.2 ± 19.61 and 142.67 ± 57 mg respectively) and mice treated with 
the higher (55.42 ± 21.67 mg) and medium doses (60 ± 35.21 mg). This effect was not 
appreciable in the group treated with the lowest dose, thus suggesting that the 
therapeutic effect of therapy is dose-dependent (Figure 5B). 
Marked differences were also observed at the histological level. Thus, a 
comparison of tumors from the control and treated groups showed a selective and dose-
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dependent reduction in tumor area as a result of treatment. Indeed, treatment acts in a 
specific and selective way on tumor cells, as demonstrated by evaluating the prognostic 
factors MUC 1 and Ki-67 by way of inmunohistochemical assays. In contrast, treatment 
has no adverse effects on accessory structures, animal health and behavior, or in the 
post-mortem exploration. 
The data obtained show the antitumor efficacy of the system in breast cancer, with 
the lack of visual toxic symptoms in the treated animals support its use as an efficient 
device for breast cancer gene therapy. 
5. CONCLUSION 
We have developed a double-lock device comprising the biopolymer ELR-PEG-
5TR1 and the therapeutic agent pDhMUC1-ricin. Binding of 5TR1 to the ELR was 
achieved via click chemistry, and the resulting ELR-PEG-5TR1 was able to form stable 
polyplexes in the presence of pDNA with a suitable size for gene-delivery purposes. 
The aptamer present in the corona binds to a specific target in tumor cells (the 
transmembrane underglycosylated MUC1 glycoprotein), and selective overexpression 
of the toxin ricin gene exclusively inside human breast cancer cells is obtained due to 
the presence of the MUC promoter, which controls its expression. Moreover, this 
double-lock device is able to target breast cancer cells, internalizing and expressing the 
toxic ricin gene inside these cells. This system has shown promising results in vivo, thus 
providing direct proof that ELRs can be linked to aptamers for use in breast cancer 
suicide gene therapy. Most previous studies with ricin have been performed in 
immunotherapy with RTA or the holotoxin and blocking of the galactose binding sites 
[40]. To the best of our knowledge, this is the first time that the whole ricin gene has 
been transferred into target cells as part of suicide gene therapy in breast cancer. Indeed, 
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the results presented herein will form the basis of future studies into the non-viral ELR 
designed herein and the therapeutic plasmid-containing ricin. 
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Figure 1. Polyplex size and morphology of ELR-5TR1-pDNA. (A) Graph 
showing the scattered light intensity (percent) as function of size (diameter, nm). (B) 
TEM image of polyplexes formed at a 50/1/4 N/P/Papt (8500 ELR/1 pDNA/2000 
5TR1) ratio. The scale bar corresponds to 100 nm. 
Figure 1 Legends
Figure 2
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Figure 2. Luciferase expression by pDhMUC1-luciferase contained in ELR-
5TR1- pDhMUC1-luciferase polyplexes. Nude pDhMUC1-luciferase and Turbofect-
pDhMUC1-luciferase were used as negative and positive controls, respectively. ELR 
polyplexes were used as control for aptamer specificity. Luciferase activity is expressed 
in RLU/mg protein lysate. The results are expressed on a logarithmic scale as 
mean±standard error of three independent experiments. **: p<0.01, ***: p<0.001 
 
Figure 2 legend
Figure 3
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Figure 3 Cytotoxicity of pDhMUC1-ricin polyplexes for MCF-7 and HFF1 
cells. Incubation with the transfectant polyplex was followed by 48 hours under 
standard culture conditions. These results are representative of three independent 
experiments, with four replicates in each experiment. Values are shown as mean +/- SD. 
***: p<0.001 
 
Figure 3 legend
Figure 4
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Figure 4. In vivo antitumor activity following treatment with ELR-5TR1-
pDhMUC1-ricin complexes and negative controls. (A) Tumor volume evolution during 
23 days after five injections of placebo, luciferase polyplex 70 nM control group, 1.7, 
17 and 70 nM of therapeutic plasmid and 70 nM of pDhMUC1-luciferase. Arrows 
indicate the injections of treatments. (B) Tumor mass evaluation after necropsy. Data 
represent the mean ± S.D. A statistical analysis showed significant differences (*: 
p<0.05, **: p<0.01, ***: p<0.001). 
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Figure 5. Microphotographs showing histological staining of tumors with 
hematoxylin-eosin (H&E) stain. The columns contain photographs of histological 
sections: A control tumor; B 1.7 nM and C 70 nM treatment dose. Scale bar:1000 
micrometers 
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Figure 6
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Figure 6. Microphotographs showing histological Picro red staining of tumors. 
A: control and B: 70 nM treated tumors and sections thereof. Scale bar: 1000 
micrometers. 
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Figure 7
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Figure 7. Expression of tumor and vascularization markers characterization. 
Immunohistochemistry was performed with specific antibodies against MUC1 or CD31 
(immunofluorescence staining green) then stained with nuclear marker DAPI (blue).  
Photographs of the tumor (left) and sections thereof (right). In the sections is shown 
only the IHC staining to appreciate better IHC signals. Panel A: placebo, panel B: 70 
nM dose treated group. Scale bar of tumors: 1000 micrometers, sections: 100 
micrometers. 
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